What is LONA's other commercial liabilities?

LONA (LONA) reported other commercial liabilities of $4.42M in Q1 2026.

How has LONA's other commercial liabilities changed year-over-year?

LONA's other commercial liabilities increased by 5.4% year-over-year, from $4.2M to $4.42M.

Over 5 years (2020 to 2025), LONA's other commercial liabilities has grown at a 9.7% compound annual growth rate (CAGR), from $3.12M to $4.96M.

Inhibrx Biosciences, Inc.INBX

——

Dogwood TherapeuticsDWTX

——

Operating income-$17.2M-80.5%

Net income-$32.9M-260%

EPS (diluted)-$1.73+26.1%

Cash & equivalents$32.8M+24.3%

Total debt$691.0K-38.2%

Total equity$49.3M+32.1%

Total assets$71.6M+64.5%

Operating cash flow-$20.9M-42.5%

CapEx$28.0K-15.2%

Free cash flow-$26.0M+1.1%

Market cap$86.33M+223%

Enterprise value$54.18M—

Return on equity-298.8%-726pp

Debt / equity0×0.0×

Current ratio10.4×+3.1×

Reported directly by LONA in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.

The official record: LONA’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is LONA's other commercial liabilities?: LONA (LONA) reported other commercial liabilities of $4.42M in Q1 2026.
How has LONA's other commercial liabilities changed year-over-year?: LONA's other commercial liabilities increased by 5.4% year-over-year, from $4.2M to $4.42M.
What is the long-term trend for LONA's other commercial liabilities?: Over 5 years (2020 to 2025), LONA's other commercial liabilities has grown at a 9.7% compound annual growth rate (CAGR), from $3.12M to $4.96M.